Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Baroreflex sensitivity (BRS) quantifies the responsiveness of the arterial baroreflex, expressed as the change in interbeat interval (IBI) per unit change in blood pressure (BP)[1][8]. The baroreflex is a key homeostatic mechanism, adjusting heart rate via autonomic nervous system activity to rapidly counteract fluctuations in systemic blood pressure[5]. Impaired BRS is a marker of cardiovascular autonomic dysfunction and is associated with poor prognosis in conditions such as heart failure, hypertension, and after myocardial infarction[7][8]. BRS can be measured experimentally using pharmacological agents (e.g., phenylephrine), maneuvers (Valsalva), or via spontaneous recordings of heart rate and blood pressure variability[1][7]. Baroreflex activation therapy is being explored as a strategy to treat resistant hypertension and heart failure by modulating baroreceptor neuronal pathways, but BRS itself is a clinical parameter, not a molecular target[5].
Not applicable; BRS is a measure, not a molecular target.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Baroreflex sensitivity (BRS).